Increased Circulating CD62E + Endothelial Extracellular Vesicles Predict Severity and in- Hospital Mortality of COVID-19 Patients.

Autor: Mezine F; Université Paris Cité, INSERM, PARCC, F-75015, Paris, France., Guerin CL; Cytometry core, Institut Curie, F-75005, Paris, France.; Université Paris Cité, INSERM, Innovative Therapies in Haemostasis, F-75006, Paris, France., Philippe A; Université Paris Cité, INSERM, Innovative Therapies in Haemostasis, F-75006, Paris, France.; Hematology department and Biosurgical research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, F-75015, Paris, France., Gendron N; Université Paris Cité, INSERM, Innovative Therapies in Haemostasis, F-75006, Paris, France.; Hematology department and Biosurgical research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, F-75015, Paris, France., Soret L; Université Paris Cité, INSERM, Innovative Therapies in Haemostasis, F-75006, Paris, France.; Hematology department and Biosurgical research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, F-75015, Paris, France., Sanchez O; Université Paris Cité, INSERM, Innovative Therapies in Haemostasis, F-75006, Paris, France.; Respiratory disease department and Biosurgical research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, F-75015, Paris, France., Mirault T; Université Paris Cité, INSERM, PARCC, F-75015, Paris, France.; Vascular medicine department, AP-HP, Georges Pompidou European Hospital, F-75015, Paris, France., Diehl JL; Université Paris Cité, INSERM, Innovative Therapies in Haemostasis, F-75006, Paris, France.; Intensive care medicine department and Biosurgical research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, F-75015, Paris, France., Chocron R; Université Paris Cité, INSERM, PARCC, F-75015, Paris, France.; Emergency department, AP-HP, Georges Pompidou European Hospital, F-75015, Paris, France., Boulanger CM; Université Paris Cité, INSERM, PARCC, F-75015, Paris, France. Chantal.boulanger@inserm.fr., Smadja DM; Université Paris Cité, INSERM, Innovative Therapies in Haemostasis, F-75006, Paris, France. david.smadja@aphp.fr.; Hematology department and Biosurgical research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, F-75015, Paris, France. david.smadja@aphp.fr.
Jazyk: angličtina
Zdroj: Stem cell reviews and reports [Stem Cell Rev Rep] 2023 Jan; Vol. 19 (1), pp. 114-119. Date of Electronic Publication: 2022 Aug 18.
DOI: 10.1007/s12015-022-10446-5
Abstrakt: COVID-19 and infectious diseases have been included in strategic development goals (SDG) of United Nations (UN). Severe form of COVID-19 has been described as an endothelial disease. In order to better evaluate Covid-19 endotheliopathy, we characterized several subsets of circulating endothelial extracellular vesicles (EVs) at hospital admission among a cohort of 60 patients whose severity of COVID-19 was classified at the time of inclusion. Degree of COVID-19 severity was determined upon inclusion and categorized as moderate to severe in 40 patients and critical in 20 patients. We measured citrated plasma EVs expressing endothelial membrane markers. Endothelial EVs were defined as harboring VE-cadherin (CD144+), PECAM-1 (CD31 + CD41-) or E-selectin (CD62E+). An increase in CD62E + EV levels on admission to the hospital was significantly associated with critical disease. Moreover, Kaplan-Meier survival curves for CD62E + EV level showed that level ≥ 88,053 EVs/μL at admission was a significant predictor of in hospital mortality (p = 0.004). Moreover, CD62E + EV level ≥ 88,053 EV/μL was significantly associated with higher in-hospital mortality (OR 6.98, 95% CI 2.1-26.4, p = 0.002) in a univariate logistic regression model, while after adjustment to BMI CD62E + EV level ≥ 88,053 EV/μL was always significantly associated with higher in-hospital mortality (OR 5.1, 95% CI 1.4-20.0, p = 0.01). The present findings highlight the potential interest of detecting EVs expressing E-selectin (CD62) to discriminate Covid-19 patients at the time of hospital admission and identify individuals with higher risk of fatal outcome.
(© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: